Albireo Total Asset
ALBODelisted Stock  USD 44.15 0.75 1.67% 
Albireo Pharma fundamentals help investors to digest information that contributes to Albireo Pharma's financial success or failures. It also enables traders to predict the movement of Albireo Stock. The fundamental analysis module provides a way to measure Albireo Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Albireo Pharma stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Albireo  Total Asset 
Albireo Total Asset Analysis
Albireo Pharma's Total Asset is everything that a business owns. It is the sum of current and longterm assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
More About Total Asset  All Equity Analysis
2020  2021  2022  2023 (projected)  
Revenues USD  8.31 M  40.58 M  46.67 M  50.35 M 
Revenues  8.31 M  40.58 M  46.67 M  50.35 M 
Total Asset  =  Tangible Assets  +  Intangible Assets 
Current Albireo Pharma Total Asset  302.05 M 
Most of Albireo Pharma's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Albireo Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Albireo Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Albireo Pharma is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Total Asset. Since Albireo Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Albireo Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Albireo Pharma's interrelated accounts and indicators.
Albireo Total Asset Historical Pattern
Today, most investors in Albireo Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Albireo Pharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Albireo Pharma total asset as a starting point in their analysis.
Albireo Pharma Total Asset 
Timeline 
Total Asset is typically divided on the balance sheet on current asset and longterm asset. Longterm is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
CompetitionAlbireo Total Assets
Total Assets 

Based on the latest financial disclosure, Albireo Pharma has a Total Asset of 302.05 M. This is 95.98% lower than that of the Biotechnology sector and 84.71% lower than that of the Health Care industry. The total asset for all United States stocks is 98.97% higher than that of the company.
Albireo Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Albireo Pharma's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Albireo Pharma could also be used in its relative valuation, which is a method of valuing Albireo Pharma by comparing valuation metrics of similar companies.Albireo Pharma is currently under evaluation in total asset category among related companies.
Albireo Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Albireo Pharma from analyzing Albireo Pharma's financial statements. These drivers represent accounts that assess Albireo Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Albireo Pharma's important valuation drivers and their relationship over time.
2018  2019  2020  2021  2022  2023 (projected)  
Net Income Per Employee  (1.18 M)  (1.14 M)  (1.19 M)  (261.77 K)  (301.03 K)  (324.8 K)  
Revenue Per Employee  326.67 K  175.2 K  92.06 K  312.15 K  358.97 K  360.48 K  
Average Assets  199.19 M  172.87 M  240.71 M  266.95 M  307 M  331.23 M  
Earnings Before Interest Taxes and Depreciation Amortization EBITDA  (41.21 M)  (57.29 M)  (96.08 M)  (19.82 M)  (17.84 M)  (19.25 M)  
Earnings Before Interest Taxes and Depreciation Amortization USD  (41.21 M)  (57.29 M)  (96.08 M)  (19.82 M)  (17.84 M)  (19.25 M)  
Earnings before Tax  (46.09 M)  (62.72 M)  (107.63 M)  (34.03 M)  (30.63 M)  (33.04 M)  
Average Equity  142.23 M  105.98 M  148.89 M  154.69 M  177.89 M  191.93 M  
Enterprise Value  120.02 M  179.83 M  446.4 M  196.32 M  225.76 M  188.69 M  
Free Cash Flow  (26.85 M)  (53.46 M)  (101.11 M)  (108.02 M)  (97.22 M)  (99.78 M)  
Invested Capital  (8.5 M)  (2.96 M)  1.41 M  1.34 M  1.54 M  1.66 M  
Invested Capital Average  (5.73 M)  (3.27 M)  2.73 M  (872 K)  (784.8 K)  (846.76 K)  
Market Capitalization  293.62 M  322.49 M  715.59 M  449 M  516.35 M  557.11 M  
Tangible Asset Value  168.21 M  147.81 M  268.35 M  284.79 M  327.51 M  353.37 M  
Working Capital  154.82 M  122.88 M  236.58 M  223.58 M  257.12 M  277.42 M 
Albireo Fundamentals
Return On Equity  (0.93) %  
Return On Asset  (0.25) %  
Profit Margin  (2.29) %  
Operating Margin  (2.15) %  
Current Valuation  259.98 M  
Shares Outstanding  20.74 M  
Shares Owned by Insiders  3.60 %  
Shares Owned by Institutions  96.40 %  
Number of Shares Shorted  553.91 K  
Price to Earning  (4.16) X  
Price to Book  4.30 X  
Price to Sales  7.35 X  
Revenue  40.58 M  
Gross Profit  39.22 M  
EBITDA  (19.82 M)  
Net Income  (34.03 M)  
Cash and Equivalents  180.97 M  
Cash per Share  9.23 X  
Total Debt  10 M  
Debt to Equity  0.18 %  
Current Ratio  4.49 X  
Book Value Per Share  4.84 X  
Cash Flow from Operations  (107.56 M)  
Short Ratio  0.86 X  
Earnings Per Share  (6.66) X  
Target Price  44.0  
Number of Employees  130  
Beta  1.04  
Market Capitalization  915.89 M  
Total Asset  302.05 M  
Retained Earnings  (171.75 M)  
Working Capital  26.76 M  
Current Asset  28.84 M  
Current Liabilities  2.07 M  
Z Score  54.6  
Net Asset  302.05 M 
About Albireo Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Albireo Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Albireo Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Albireo Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Last Reported  Projected for 2023  
Total Assets  347.4 M  374.8 M  
Total Assets Per Share  18.00  18.47  
Net Current Assets as percentage of Total Assets  85.12  91.09  
Average Assets  307 M  331.2 M  
Tangible Asset Value  327.5 M  353.4 M 
Be your own money manager
Our tools can tell you how much better you can do entering a position in Albireo Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate riskadjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Correlation Analysis Now
Correlation AnalysisReduce portfolio risk simply by holding instruments which are not perfectly correlated 
All Next  Launch Module 
Pair Trading with Albireo Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Albireo Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Albireo Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Albireo Pharma
  0.87  ABIO  ARCA Biopharma  Fiscal Quarter End 31st of March 2023  PairCorr  
  0.71  ACER  Acer Therapeutics  Financial Report 15th of May 2023  PairCorr  
  0.59  AADI  Aadi Bioscience  Earnings Call This Week  PairCorr  
  0.54  ACGN  Aceragen  Earnings Call This Week  PairCorr 
The ability to find closely correlated positions to Albireo Pharma could be a great tool in your taxloss harvesting strategies, allowing investors a quick way to find a similarenough asset to replace Albireo Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Albireo Pharma  that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Albireo Pharma to buy it.
The correlation of Albireo Pharma is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between 1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Albireo Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Albireo Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Albireo Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better riskadjusted return on your portfolios.Please continue to Trending Equities. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Albireo Stock
If you are still planning to invest in Albireo Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Albireo Pharma's history and understand the potential risks before investing.
Probability Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years  
Portfolio Rebalancing Analyze riskadjusted returns against different time horizons to find assetallocation targets  
RiskReturn Analysis View associations between returns expected from investment and the risk you assume  
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on selflearning algorithm to remember stocks you like  
Global Correlations Find global opportunities by holding instruments from different markets  
Content Syndication Quickly integrate customizable finance content to your own investment portal  
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.  
Equity Valuation Check real value of public entities based on technical and fundamental data  
Watchlist Optimization Optimize watchlists to build efficient portfolio or rebalance existing positions based on meanvariance optimization algorithm  
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges  
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing  
Transaction History View history of all your transactions and understand their impact on performance  
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated 